Showing results (341-350 of 401) with videos related to

Sort By:
Pageof 41
Nature Metabolism|September 20, 2019
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinomaWen Cai Zhang, Julie M Wells, Kin-Hoe Chow, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
A microRNA atlas of the human prefrontal cortex across the adult lifespanIrais Erendira Valenzuela-Arzeta, Pourya Naderi Yeganeh, Anupama Rai, et al.
Nature Communications|May 21, 2024
Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait lociChristos Miliotis, Yuling Ma, Xanthi-Lida Katopodi, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2016
The discovery of quinoline based single-ligand human H1 and H3 receptor antagonistsPanayiotis A Procopiou, Rachael A Ancliff, Paul M Gore, et al.
European Journal of Medicinal Chemistry|March 19, 2016
2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosisLena Shukla, Laura A Ajram, Malcolm Begg, et al.
European Journal of Clinical Pharmacology|March 14, 2018
Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participantsCharlotte H Maden, David Fairman, Michelle Chalker, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2023
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participantsVassilios Aslanis, Robert J Slack, Alison C MacKinnon, et al.
Journal of Medicinal Chemistry|December 12, 2024
Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of CancerKristoffer Peterson, Ulf J Nilsson, Lise Gravelle, et al.
Journal of Medicinal Chemistry|April 29, 2026
An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 InhibitorFredrik R Zetterberg, Kristoffer Peterson, Ulf J Nilsson, et al.
Haematologica|March 5, 2026
GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa studyRichard F Schlenk, Claire N Harrison, Francesca Palandri, et al.
Pageof 41